Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab - Genentech/Novartis Ophthalmics

Drug Profile

Ranibizumab - Genentech/Novartis Ophthalmics

Alternative Names: ACCENTRIX; AMD Fab; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; RG-6321; rhuFab V2; rhuFab V2 AMD; Susvimo; SusvimoTM; VEGF antibody fragment

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Novartis Ophthalmics; Roche
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinopathy of prematurity; Wet age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema; Retinopathy of prematurity; Wet age-related macular degeneration
  • Phase I/II Polypoidal choroidal vasculopathy
  • Discontinued Retinal telangiectasis

Most Recent Events

  • 01 Feb 2024 Chugai Pharmaceutical plans regulatory filing for Diabetic macular oedema and Wet-age-related macular degeneration in Japan (Intraocular, Implant) in 2025 (Chugai pharmaceutical pipeline, February 2024)
  • 18 Jan 2024 Hoffmann-La Roche withdraws the phase III Diagrid trial in Wet age-related macular degeneration in United Kingdom, United Arab Emirates, Argentina, Austria, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Multinational, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Switzerland and Thailand (Intraocular) because Roche/Genentech initiated an immediate pause of all new PDS implantations (NCT05126966) (EudraCT2021-003226-71 )
  • 23 Aug 2023 Chugai Pharmaceutical plans regulatory filing for Wet age related macular degeneration in or after 2026 (Roche pipeline, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top